19
October
IMP – [Non-rated] – Brief – On a smooth growth
Imexpharm (IMP) issued 3Q22’s business results on Oct 18, with a revenue of VND418bn (+63% yoy and +18% qoq) and a NPAT of VND56bn (+81% yoy and +19% qoq). 9M22 revenue and NPAT were VND1,087bn/VND155bn (+25%/+27% yoy), fulfilling 52%/48% of their annual guidance.